Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Novartis (NOVN.XSWX) generated about $56.6 billion in revenue and $13.5 billion in net income (a 23.9% net margin) over the trailing twelve months, growing at roughly 6.5% a year. Figures are from SEC filings; this is analysis, not investment advice.
Novartis generated about $56.6 billion in revenue over the trailing twelve months. Revenue has grown at roughly 6.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Yes, Novartis reported about $13.5 billion in net income over the trailing twelve months, a net profit margin of roughly 23.9%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
Novartis runs a gross margin of about 75.4%, an operating margin of about 30.4%, a net margin of about 23.9%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
Novartis's revenue has compounded at roughly 6.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside NOVN.XSWX's margins and free cash flow. This is analysis from SEC filings, not investment advice.